Under the terms of the agreement, Midwinter will continue to distribute Sun’s portfolio of both injectable and solid dose drugs for a further 2 years and then on a continuing 12 month rolling basis thereafter. Midwinter will continue to be the sole point of contact for all clinical trial supply enquiries and orders for these products. Midwinter have helped increase Sun’s exposure to clinical trials by increasing sales consistently over the last 24 months.
Midwinter Director Ben Everington commented;
“We look forward to continuing to work with Sun and are pleased that they have chosen to extend this pivotal agreement, which is a great step for both companies. Midwinter have been able to demonstrate increased sales of Sun products into clinical trials to help them access this important revenue stream. We are also delighted that since Sun Pharma’s recent acquisition of Ranbaxy, we are able to extend our service to Ranbaxy’s portfolio of generic medicines which further compliments our ability to offer unrivalled supply solutions to global clinical trials”.
Sun Pharmaceuticals Head of UK Hospital Supply, Jim McCarthy commented;
“Sun and Midwinter have formed a strong partnership over first 2 years of the agreement, which we are delighted to now extend. Midwinter’s focus and expertise in the clinical trial sector has helped us reach new customers and broaden the reach of Sun’s products. We are looking forward to working alongside each other for the years ahead”